help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology Vol. 6, No. 12 2167-2174
doi:10.1210/me.6.12.2167
Copyright © 1992 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jiang, S. Y.
Right arrow Articles by Jordan, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jiang, S. Y.
Right arrow Articles by Jordan, V. C.

Molecular Endocrinology, Vol 6, 2167-2174, Copyright © 1992 by Endocrine Society


ARTICLES

Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER

SY Jiang, SM Langan-Fahey, AL Stella, R McCague and VC Jordan
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792.

The antiestrogen tamoxifen is used in the treatment of hormone- responsive breast cancer. However, therapeutic failure has frequently been observed in both patients and animal models after long term treatment. We have studied the effect of a point mutation that leads to the substitution of Val for Gly at codon 400 in the ligand-binding domain of the estrogen receptor (ER) on estrogenic and antiestrogenic activities of 4-hydroxytamoxifen (4-OHT) and its derivatives. Stable ER transfectants derived from MDA-MB-231 CL10A, an ER-negative breast cancer cell line, have been used in these studies. 4-OHT and its fixed ring derivatives showed more estrogen-like activity in ER transfectants than in MCF-7, an ER-positive breast cancer cell line. In this study, 4- OHT was a partial agonist of cell growth in the transfectant S30 cells, which express the wild-type ER. However, it was a full agonist in the mutant ER transfectant ML alpha 2H, which expressed ER with Val at codon 400. The increased estrogenic activity of 4-OHT in ML alpha 2H cells was not due to the preferential isomerization of trans 4-OHT to cis 4-OHT, since the nonisomerizable fixed ring trans 4-OHT was a partial agonist for cell growth in S30 cells and was a full agonist in ML alpha 2H cells. Transient transfection using a reporter plasmid containing an estrogen response element demonstrated that fixed ring trans 4-OHT had estrogenic activity in ML alpha 2H cells.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
Endocr. Rev.Home page
M. H. Herynk and S. A. W. Fuqua
Estrogen Receptor Mutations in Human Disease
Endocr. Rev., December 1, 2004; 25(6): 869 - 898.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
V. S. Wilson, K. Bobseine, C. R. Lambright, and L. E. Gray Jr.
A Novel Cell Line, MDA-kb2, That Stably Expresses an Androgen- and Glucocorticoid-Responsive Reporter for the Detection of Hormone Receptor Agonists and Antagonists
Toxicol. Sci., March 1, 2002; 66(1): 69 - 81.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. P. L. Bhat, D. Lantvit, K. Christov, R. G. Mehta, R. C. Moon, and J. M. Pezzuto
Estrogenic and Antiestrogenic Properties of Resveratrol in Mammary Tumor Models
Cancer Res., October 1, 2001; 61(20): 7456 - 7463.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Liu, E.-S. Lee, A. D. L. Reyes, J. W. Zapf, and V. C. Jordan
Silencing and Reactivation of the Selective Estrogen Receptor Modulator-Estrogen Receptor {{alpha}} Complex
Cancer Res., May 1, 2001; 61(9): 3632 - 3639.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
H.-L. C. Liu, E. Golder-Novoselsky, M. H. Seto, L. Webster, J. McClary, and D. A. Zajchowski
The Novel Estrogen-Responsive B Box Protein (EBBP) Gene Is Tamoxifen Regulated in Cells Expressing an Estrogen Receptor DNA-Binding Domain Mutant
Mol. Endocrinol., November 1, 1998; 12(11): 1733 - 1748.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
J. I. Macgregor and V. C. Jordan
Basic Guide to the Mechanisms of Antiestrogen Action
Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-i. Wong, W. R. Kelce, M. Sar, and E. M. Wilson
Androgen Receptor Antagonist versus Agonist Activities of the Fungicide Vinclozolin Relative to Hydroxyflutamide
J. Biol. Chem., August 25, 1995; 270(34): 19998 - 20003.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
M. Morrow and V. C. Jordan
Molecular Mechanisms of Resistance to Tamoxifen Therapy in Breast Cancer
Arch Surg, November 1, 1993; 128(11): 1187 - 1191.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society